Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
SEHK:2315 Voorraadrapport
Marktkapitalisatie: HK$2.3b
Biocytogen Pharmaceuticals (Beijing) Balans Gezondheid
Financiële gezondheid criteriumcontroles 4/6 Biocytogen Pharmaceuticals (Beijing) heeft een totaal eigen vermogen van CN¥744.2M en een totale schuld van CN¥395.5M, wat de schuld-eigenvermogensverhouding op 53.1% brengt. De totale activa en totale passiva bedragen respectievelijk CN¥2.4B en CN¥1.7B.
Belangrijke informatie
53.1%
Verhouding schuld/eigen vermogen
Rente dekkingsratio n/a Contant CN¥424.07m Aandelen CN¥744.24m Totaal verplichtingen CN¥1.69b Totaal activa CN¥2.43b
Recente financiële gezondheidsupdates
Toon alle updates
First half 2024 earnings released: CN¥0.13 loss per share (vs CN¥0.48 loss in 1H 2023) Sep 28
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. to Report Q2, 2024 Results on Aug 28, 2024 Aug 16
Is Biocytogen Pharmaceuticals (Beijing) (HKG:2315) A Risky Investment? May 08
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s (HKG:2315) Price Is Right But Growth Is Lacking Apr 03
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Annual General Meeting, May 28, 2024 Mar 29
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Annual General Meeting, May 28, 2024 Mar 28
Full year 2023 earnings released: CN¥0.96 loss per share (vs CN¥1.58 loss in FY 2022) Mar 28
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024 Mar 16
New minor risk - Share price stability Feb 16
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Approves Election of Ms. Li Yan as A Non-Employee Representatives Supervisor of the Company Dec 13
New minor risk - Share price stability Oct 06
Biocytogen Pharmaceuticals' RenMice Series-Fully Human Antibody and TCR Mouse Models-Showcase Biocytogen's Capabilities to Innovate the Discovery of Biologic Drugs Sep 15
Forecast to breakeven in 2025 Aug 31
First half 2023 earnings released: CN¥0.48 loss per share (vs CN¥0.73 loss in 1H 2022) Aug 30
New minor risk - Profitability Aug 29
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Announces Project Integrum Achieves Milestone Progress, Accelerating Antibody Business Growth Aug 18
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. to Report First Half, 2023 Results on Aug 28, 2023 Aug 16
Forecast to breakeven in 2025 Mar 29
Full year 2022 earnings: EPS and revenues miss analyst expectations Mar 28
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Launches Rennano Mouse, Fully Human Heavy Chain Antibody Platform to Accelerate Nanobody Drug Discovery Dec 30
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Announces FDA Clearance of IND Application for Bispecific Antibody YH008 Dec 19
Less than half of directors are independent Nov 16
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Announces Management Appointments Nov 08
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Announces Resignation of Huang Xiaolu as Non-Executive Director and A Member of the Strategy Development Committee Oct 18
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. to Present at Biojapan2022, Introducing Innovative R&D Platforms, Bispecific ADC Programs and Pipeline Progress Sep 28
First half 2022 earnings released: EPS: CN¥0 (vs CN¥0 in 1H 2021) Sep 27
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has completed an IPO in the amount of HKD 548.74937 million. Sep 01
Less than half of directors are independent Sep 01
Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( CN¥766.1M ) 2315 } overtreffen de korte termijn passiva ( CN¥572.6M ).
Langlopende schulden: De kortetermijnactiva van 2315 ( CN¥766.1M ) dekken de langetermijnschulden ( CN¥1.1B ) niet.
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: 2315 heeft meer geld in kas dan de totale schuld.
Schuld verminderen: Er zijn onvoldoende gegevens om te bepalen of de schuld/eigen vermogen-ratio van 2315 de afgelopen 5 jaar is gedaald.
Analyse van de cashflow Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: 2315 heeft op basis van de huidige vrije kasstroom voldoende cash runway voor meer dan 3 jaar.
Voorspelling contante baan: 2315 heeft voldoende kasruimte voor 1.5 jaar als de vrije kasstroom blijft groeien met een historisch percentage van 35.5 % per jaar.
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
